UCB

UCB is a multinational biopharmaceutical company headquartered in Brussels, Belgium. UCB is an international company with a revenue of €4.178 billion in 2016 which focuses primarily on research and development, specifically involving medications centered on epilepsy, Parkinson’s, and Crohn’s diseases. 

UCB SA engages in the research, development, and commercialization of pharmaceutical and biotechnology products. It offers medicinal products for central nervous system and immunology disorders under the Cimzia, Xyzal, Zyrtec, Tussionex, Lortab, Vimpat, Keppra, and Neupro. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.